acute%20pericarditis
ACUTE PERICARDITIS

Pericarditis is the inflammation of the pericardial sac and accounts for 5% of visits to the emergency room for chest pain without myocardial infarction.

The patient experiences chest pain that is sharp, pleuritic and improves with sitting up and leaning forward.

Acute pericarditis is characterized by new-onset pericarditis with at least 2 of the following:

  • Pericarditic chest pain
  • Pericardial friction rubs
  • New or worsening pericardial effusion
  • ECG finding of a new diffuse ST-segment elevation or PR depression
Drug Information

Indication: Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; rel...

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Adjuvant of a maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylit...

Indication: Severe hypersensitivity & dermatological reaction; severe acute & chronic inflammatory & allergic ...

Indication: Adjunctive therapy for short-term management of acute episode or exacerbation post-traumatic OA, synovitis or ...

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
2 days ago
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.